Arvinas vs Iovance Biotherapeutics
Arvinas and Iovance Biotherapeutics are similar in size: $263m and $264m of revenue in their latest fiscal years. Iovance Biotherapeutics grew faster (60.6% against -0.3%). Arvinas kept more of each dollar of sales as profit: a net margin of -30.8% against -148.4%.
| Latest fiscal year | ArvinasARVN, 2025 | Iovance BiotherapeuticsIOVA, 2025 |
|---|---|---|
| Revenue | $263m | $264m |
| Revenue growth | -0.3% | 60.6% |
| Net income | −$80.8m | −$391m |
| Operating margin | -45.1% | — |
| Net margin | -30.8% | -148.4% |
| Return on equity | -16.2% | -55.5% |
| Free cash flow | −$276m | −$336m |
| Cash | $143m | $163m |
| Total debt | $600,000 | — |
| Debt to equity | 0.1% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $91.9m | — |
| Employees | 246 | 975 |
| Market value | $462m | $3.95bn |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 1 buys, 23 sales | 0 buys, 0 sales |